Real-World Immuno-Radiotherapy for Advanced NSCLC

NCT06747026 · clinicaltrials.gov ↗

COMPLETED

Status

338

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer Non-Small Cell Cancer (NSCLC)

Interventions

DRUG: initial Sequential iRT
DRUG: initial Concurrent iRT
DRUG: RT with maintenance of ICI
DRUG: RT after discontinuation of ICI

Sponsor

Fengming Kong